［1］Sharma P，Wagner K，Wolchok JD，et al.Novel cancer immunotherapy agents with survival benefit：Recent successes and next steps［J］.Nat Rev Cancer，2011，11：805-812.
[2]Sharma P，Allison JP.Immune checkpoint targeting in cancer therapy：Toward combination strategies with curative potential［J］.Cell，2015，161：205-214.
[3]Topalian SL，Weiner GJ，Pardoll DM.Cancer immunotherapy comes of age［J］.J Clin Oncol，2011，29：4828-4836.
[4]Mellman I，Coukos G，Dranoff G.Cancer immunotherapy comes of age［J］.Nature，2011，480：480-489.
[5]Vinay DS，Ryan EP，Pawelec G，et al.Immune evasion in cancer：Mechanistic basis and therapeutic strategies［J］.Seminars in Cancer Biology，2015，35：S185-S198.
[6]Berezhnoy A，Castro I，Levay A，et al.Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity［J］.J Clin Investigation，2014，124(1)：188-197.
[7]Son CH，Bae JH，Shin DY，et al.CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model［J］.J Immunotherapy，2014，37(1)：1-7.
[8]Postow MA，Yuan J，Kitano S，et al.Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma［J］.Methods in Molecular Biology，2014，1102：83-95.
[9]Ribas A.Releasing the brakes on cancer immunotherapy［J］.N Engl J Med，2015，373：1490-1492.
[10]Grosso JF，Jure-Kunkel MN，Jure-Kunkel MN.CTLA-4 blockade in tumor models：An overview of preclinical and translational research［J］.Cancer Immun，2013，13：5.
[11]Leeneman B，Franken MG，Jochems A，et al.Improved survival with ipilimumab in patients with advanced melanoma in real-world clinical practice：First results of the dutch melanoma treatment registry［J］.Value in Health，2015，18(7)：440-441.
[12]Robert C，Thomas L，Bondarenko I，et al.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma［J］.N Engl J Med，2011，364(26)：2517-2526.
[13]Chen DS，Mellman I.Oncology meets immunology：The cancer-immunity cycle［J］.Immunity，2013，39：1-10.
[14]Ji M，Liu Y，Li Q，et al.PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation［J］.J Translational Medicine，2015，13(1)：1-6.
[15]Okazaki T，Chikuma S，Iwai Y，et al.A rheostat for immune responses：The unique properties of PD-1 and their advantages for clinical application［J］.Nat Immunol，2013，14(12)：1212-1218.
[16]Jia R，Jiao Z，Xu X，et al.Functional significance of B7-H1 expressed by human uveal melanoma cells［J］.Molecular Medicine Reports，2011，4(1)：163-167.
[17]Taube JM，Klein A，Brahmer JR，et al.Association of PD-1，PD-1 ligands，and other features of the tumor immune microenvironment with response to anti-PD-1 therapy［J］.Clin Cancer Res，2014，20(19)：5064-5074.
[18]Topalian SL，Hodi FS，Brahmer JR，et al.Safety，activity，and immune correlates of anti-PD-1 antibody in cancer［J］.N Engl J Med，2012，366：2443-2454.
[19]Topalian SL，Sznol M，McDermott DF，et al.Survival，durable tumor remission，and long-term safety in patients with advanced melanoma receiving nivolumab［J］.J Clin Oncol，2014，32：1020-1030.
[20]Takaya S，Saito H，Ikeguchi M.Upregulation of immune checkpoint molecules，PD-1 and LAG-3，on CD4+ and CD8+ T cells after gastric cancer surgery［J］.Yonago Acta Medica，2015，58(1)：39-44.
[21]Drake CG，Lipson EJ，Brahmer JR.Breathing new life into immunotherapy：Review of melanoma，lung and kidney cancer［J］.Nature Reviews Clin Oncol，2014，11(1)：24-37.
[22]Brahmer JR，Tykodi SS，Chow LQM，et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer［J］.N Engl J Med，2012，366：2455-2465.
[23]N Poirier ，T Haudebourg ，C Brignone，et al.Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3+）-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates［J］.Clin & Exp Immunol，2011，164(2)：265-274.
[24]Liu J，Zhang S，Hu Y，et al.Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic/tumor vaccines［J］.J Immunotherapy，2016，39(4)：171-180.
[25]Sierro S，Romero P，Speiser DE.The CD4-like molecule LAG-3，biology and therapeutic applications［J］.Expert Opin Ther Targets，2011，15：91-101.
[26]Assal A，Kaner J，Pendurti G，et al.Emerging targets in cancer immunotherapy：Beyond CTLA-4 and PD-1［J］.Immunotherapy，2015，7(11)：1169-1186.
[27]Brignone C，Gutierrez M，Mefti F，et al.First-line chemoimmunotherapy in metastatic breast carcinoma：Combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity［J］.J Transl Med，2010，8：71.
[28]Freeman GJ，Casasnovas JM，Umetsu DT，et al.TIM，genes：A family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity［J］.Immunological Reviews，2010，235(1)：172-189.
[29]Mahoney KM，Rennert PD，Freeman GJ.Combination cancer immunotherapy and new immunomodulatory targets［J］.Nat Rev Drug Discov，2015，14：561-584.
[30]Melero I，Berman DM，Aznar MA，et al.Evolving synergistic combinations of targeted immunotherapies to combat cancer［J］.Nat Rev Cancer，2015，15：457-472.
[31]Curran MA，Montalvo W，Yagita H，et al.PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors［J］.Proc Natl Acad Sci USA，2010，107：4275-4280.
[32]Wolchok JD，Kluger H，Callahan MK，et al.Nivolumab plus ipilimumab in advanced melanoma［J］.N Engl J Med，2013，369：122-133.
[33]Larkin J，Hodi FS，Wolchok JD.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma［J］.N Engl J Med，2015，373：1270-1271.
[34]Melero I，Rouzaut A，Motz GT，et al.T-cell and NK-cell infiltration into solid tumors：A key limiting factor for efficacious cancer immunotherapy［J］.Cancer Discovery，2015，4：522-526.